Entia Biosciences, Inc.
ERGOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$20197
P/E Ratio—
52W High$0.0402
52W Low$0.0001
Entia Biosciences, Inc. (ERGO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ERGO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2016-12 | 2015-12 | 2014-12 | 2013-12 | 2012-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.27M | $0.35M | $0.66M | $0.31M | $0.37M |
| Cost of Revenue | $0.09M | $0.13M | $0.25M | $0.13M | $0.11M |
| Gross Profit | $0.17M | $0.22M | $0.41M | $0.18M | $0.26M |
| Gross Margin %(computed) | 65.53% | 62.24% | 62.60% | 58.34% | 70.90% |
| Operating Expenses | |||||
| R&D Expenses | $0.04M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $1.25M | $2.00M | $2.06M | $2.69M | $1.30M |
| Total Operating Expenses | $1.34M | $2.13M | $2.18M | $2.87M | $1.34M |
| Operating Income | ($1.17M) | ($1.92M) | ($1.77M) | ($2.68M) | ($1.08M) |
| Operating Margin %(computed) | -439.75% | -552.29% | -269.82% | -851.98% | -292.65% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.01M | $0.00M |
| Interest Expense | $0.08M | $0.17M | $0.34M | $0.14M | $0.26M |
| Income Before Tax | ($1.40M) | ($2.26M) | ($2.30M) | ($3.10M) | ($1.26M) |
| Income Tax Expense | $0.08M | $0.15M | $0.34M | $0.14M | $0.26M |
| Net Income | ($1.47M) | ($2.41M) | ($2.64M) | ($3.25M) | ($1.53M) |
| Net Margin %(computed) | -554.75% | -694.51% | -401.67% | — | -413.54% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.05 | $-0.10 | $-0.28 | $-0.43 | $-0.21 |
| Wtd Avg Shares | 28.14M | 24.29M | 9.44M | 7.53M | 7.30M |
| EBITDA | ($1.29M) | ($2.08M) | ($1.92M) | ($2.92M) | ($0.98M) |
| EBITDA Margin %(computed) | -487.66% | -599.23% | -292.35% | -929.05% | -265.30% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Entia Biosciences, Inc. data
About Entia Biosciences, Inc. (ERGO) Income Statement
Entia Biosciences, Inc. (ERGO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2016, ERGO reported revenue of $0.00B, gross profit of $0.00B (gross margin 65.53%), and net income of ($0.00B) — a net profit margin of -554.75%.
Frequently asked questions
ERGO · 4 questionsEntia Biosciences, Inc. (ERGO) reported revenue of $0.00B for 2016, down 23.5% year-over-year.
ERGO revenueERGO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09